Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
P/B ratio for Xilio Therapeutics, Inc. (XLO)
P/B ratio as of 2023: 0.41
According to Xilio Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.41. At the end of 2022 the company had a P/B ratio of 0.70.
P/B ratio history for Xilio Therapeutics, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.41 |
| 2022 | 0.70 |
| 2021 | 2.36 |
| 2020 | -5.28 |
| 2019 | -14886.81 |